About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Treatments and drugs
By Mayo Clinic staffMonoclonal gammopathy of undetermined significance doesn't require treatment, but your doctor is likely to recommend frequent checkups to monitor your health.
A checkup every six to 12 months may be appropriate for most people. If you have a high risk of developing a more serious condition, your doctor may recommend more frequent checkups so that if a disease such as multiple myeloma develops, it can be treated as early as possible.
If you have monoclonal gammopathy of undetermined significance and bone loss, your doctor may recommend treatment with medications called bisphosphonates that help increase your bone density. Examples of bisphosphonates include alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva) and zoledronic acid (Reclast, Zometa).
- Blade J. Monoclonal gammopathies of undetermined significance. New England Journal of Medicine. 2006;355:2765.
- Rajkumar SV, et al. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clinic Proceedings. 2010;85:945.
- Rajkumar SV. Monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home/index.html. Accessed Oct. 19, 2010.
- Monoclonal gammopathy of undetermined significance (MGUS). The Merck Manuals: The Merck Manual for Healthcare Professionals. http://www.merck.com/mmpe/print/sec11/ch144/ch144d.html. Accessed Oct. 21, 2010.
- Wadhera RK, et al. Prevalence of monoclonal gammopathy of undetermined significance: A systematic review. Mayo Clinic Proceedings. 2010;85:933.
- Landgren O, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116:1056.
- Mikhael JR (expert opinion). Mayo Clinic, Scottsdale, Ariz. Nov. 12, 2010.
Find Mayo Clinic on